30 results about "Research studies" patented technology

The invention provides systems, including apparatus, methods, and kits, for the microfluidic manipulation and / or detection of particles, such as cells and / or beads. The invention provides systems, including apparatus, methods, and kits, for the microfluidic manipulation and / or analysis of particles, such as cells, viruses, organelles, beads, and / or vesicles. The invention also provides microfluidic mechanisms for carrying out these manipulations and analyses. These mechanisms may enable controlled input, movement / positioning, retention / localization, treatment, measurement, release, and / or output of particles. Furthermore, these mechanisms may be combined in any suitable order and / or employed for any suitable number of times within a system. Accordingly, these combinations may allow particles to be sorted, cultured, mixed, treated, and / or assayed, among others, as single particles, mixed groups of particles, arrays of particles, heterogeneous particle sets, and / or homogeneous particle sets, among others, in series and / or in parallel. In addition, these combinations may enable microfluidic systems to be reused. Furthermore, these combinations may allow the response of particles to treatment to be measured on a shorter time scale than was previously possible. Therefore, systems of the invention may allow a broad range of cell and particle assays, such as drug screens, cell characterizations, research studies, and / or clinical analyses, among others, to be scaled down to microfluidic size. Such scaled-down assays may use less sample and reagent, may be less labor intensive, and / or may be more informative than comparable macrofluidic assays.

The invention provides systems, including apparatus, methods, and kits, for the microfluidic manipulation and / or detection of particles, such as cells and / or beads. The invention provides systems, including apparatus, methods, and kits, for the microfluidic manipulation and / or analysis of particles, such as cells, viruses, organelles, beads, and / or vesicles. The invention also provides microfluidic mechanisms for carrying out these manipulations and analysis. These mechanisms may enable controlled input, movement / positioning, retention / localization, treatment, measurement, release, and / or output of particles. Furthermore, these mechanisms may be combined in any suitable order and / or employed for any suitable number of times within a system. Accordingly, these combinations may allow particles to be sorted, cultured, mixed, treated, and / or assayed, among others, as single particles, mixed groups of particles, arrays of particles, heterogeneous particle sets, and / or homogeneous particle sets, among others, in series and / or in parallel. In addition, these combinations may enable microfluidic systems to be reused. Furthermore, these combinations may allow the response of particles to treatment to be measured on a shorter time scale than was previously possible. Therefore, systems of the invention may allow a broad range of cell and particle assays, such as drug screens, cell characterizations, research studies, and / or clinical analysis, among others, to be scaled down to microfluidic size. Such scaled-down assays may use less sample and reagent, may be less labor intensive, and / or may be more informative than comparable macrofluidic assays.

A system and method for managing private records and other confidential information is provided, including a patient interface that allows patients to configure privileges for various parties to access various private records or portions thereof. A database can be accessed via a privacy engine, which respects the configured privileges and allows searching for private records. A plurality of user interfaces is provided to allow records managers, patients, and interested parties to access selected private information. A clinical trials interface allows limited access to a private records database for interested parties to identify germane clinical trials and research studies. A recruitment interface allows conductors of research studies to access private records to locate appropriate research subjects.

Embodiments of the invention include integrated systems and methods of evaluating cannabis and cannabinoid products for public safety, quality control and quality assurance purposes for research and public use purposes. Embodiments of the invention facilitate suppliers and consumers of a cannabis and / or cannabinoid product to evaluate the origin, efficacy, potency, and quality of the product. Embodiments of the invention also include cannabis processing center where samples of the products are analyzed for research studies to test and set parameters for third parties. Embodiments of the invention include, for example, analyzing cannabis products to determine quality and quantity of desired components and undesired components, determining concentrations of cannabinoids in the product, and comparing measures of components in the product against regulations. Embodiments of the invention further include, for example, an online testing facility for determine whether cannabis products meet a plurality of regulations or guidelines.

Embodiments of the invention include integrated systems and methods of evaluating cannabis and cannabinoid products for public safety, quality control and quality assurance purposes for research and public use purposes. Embodiments of the invention facilitate suppliers and consumers of a cannabis and / or cannabinoid product to evaluate the origin, efficacy, potency, and quality of the product. Embodiments of the invention also include cannabis processing center where samples of the products are analyzed for research studies to test and set parameters for third parties. Embodiments of the invention include, for example, analyzing cannabis products to determine quality and quantity of desired components and undesired components, determining concentrations of cannabinoids in the product, and comparing measures of components in the product against regulations. Embodiments of the invention further include, for example, an online testing facility for determine whether cannabis products meet a plurality of regulations or guidelines.

A computer-implemented method, system, and computer program product monitors clinical research performance. One or more metrics of clinical research performance for investigator / provider / research sites across research studies are collected. The metrics include performance area, characteristic of the performance area with one or more attributes, point values for each attribute, and weight value for the characteristic. A performance score is produced for each of the entities based on the one or more metrics. A machine learning model is trained to determine performance scores based on the produced performance score for each of the entities. A request for entities is processed by applying performance scores from the machine learning model and appropriate corresponding data to a predictive model to determine resulting performance scores, rank and / or match for each of the one or more entities for a given protocol and / or assessment trigger. Actions are performed based on the resulting performance scores, rank and / or match.

A system and method for targeting relevant research activity for clinical application in response to angiogenic regulator analyses. An angiogenic analysis is performed on a patient blood sample in order to detect the level of each of at least ten angiogenic regulators. The levels of the tested regulators are used as indexes to identify relevant peer-reviewed research publications from among a large database of articles. The most relevant peer-reviewed literature reporting research and studies that have been conducted to identify, moderate, and define the mechanisms unique to individual and combinations of angiogenic regulators for various disease states are then provided to the patient and / or to the patient's physician, optionally in conjunction with a summarization of the treatment recommendations gleaned from the provided literature. The customized information delivery provides the patient and physician a range of published peer-reviewed therapeutic options and published research studies for moderating the out of range regulators to within normal range or other diagnostic significant range.

The present disclosure generally relates to techniques and user interfaces for interacting with research studies. In some embodiments, an electronic device displays a user interface that includes a task view with active tasks from multiple research studies. In some embodiments, an electronic device, while displaying a research study user interface, displays an indication of a problem that prevents enrollment in the research study when enrollment problem criteria are met. In some embodiments, an electronic device, while performing a hearing test, suspends the test and displays a restart affordance when the ambient noise level exceeds a threshold.

The invention discloses a dye-based handwriting protectant for written archives, and the protectant provided by the invention is prepared from the following raw materials in percentage by weight: 0.8-1.6% of chitosan, 0.3-0.6% of glacial acetic acids, and 97.8-98.9% of distilled water. Lab research studies show that the dye-based handwriting protectant for written archives prepared according to the mass ratio disclosed by the invention can be used for effectively preventing dye-based handwritings from diffusion when the dye-based handwritings are contacted with water, so that the mechanical strength of the whole paper is significantly improved, and the mount and repair of archival paper subjected to protection are not affected. The dye-based handwriting protectant for written archives disclosed by the invention can be applied to the protection of easily-diffused dye-based archival handwritings.

The invention discloses a genetic mark for detecting lung cancer. The genetic marker comprises an SFTPB gene, an FGFR1 gene and an FILIP1L gene. Research studies show that mRNAs (messenger ribonucleic acids) of SFTPB, FGFR1 and FILIP1L in blood mononuclear cells of patients with the lung cancer are not expressed normally, accuracy rate of diagnosis on the lung cancer reaches 98.3% after integration, and the genetic mark is much more superior to a single gene in terms of diagnosis specificity and sensitivity. Through measurement of expression quantities of the SFTPB gene, the FGFR1 gene and the FILIP1L gene in blood, diagnosis on the lung cancer (especially early lung cancer from which the patients suffer without symptoms) is achieved, so that clinical lung cancer detection rate is increased, and death rate of the patients with the lung cancer is reduced.

Methods and systems for facilitating health research through enhanced communication between research participants and researchers. Methods include communication of information related to a research study to a portable computing device of a research participant by use of an application framework and one or more modules. The one or more modules may be provided with the application framework or may include one or more modules from third-party researchers so as to allow standardization of communication from multiple research studies and differing research facilities.